Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence

Over the summer, AbbVie selected 40 undergraduate and graduate students living with CF as recipients of a $3,000 scholarship for use during the 2023-2024 academic year. The award was based on their academic excellence, creativity, and community involvement/extracurricular activities. These students now have the chance to earn the title of “2023 Thriving Undergraduate or Graduate Student,” along with an additional $22,000 in scholarship funding toward their higher education. The two winners will be determined by the number of valid votes cast by the public and the cumulative points awarded to each student by the AbbVie judging panel who evaluated the student essays and creative presentations.

“For over 30 years, the AbbVie CF Scholarship program has honored thousands of students living with CF by showcasing their accomplishments, creativity and financially supporting their pursuits of higher education,” said John Duffey, vice president, U.S. Specialty, AbbVie. “This year we continue to be inspired by these hardworking and passionate students and hope the public participates in voting for and celebrating them.”

AbbVie will announce the 2023 Thriving Undergraduate and Graduate Students in early November. 

About Cystic Fibrosis
Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs, pancreas and other organs of those living with this condition.1 In patients with CF, a thick, sticky mucus is produced in certain organs throughout the body, most commonly the lungs and digestive system. The mucus build-up in the lungs can cause difficulty breathing and may lead to life-threatening lung infections. In the pancreas, the thick mucus may prevent the release of digestive enzymes and proper food digestion, potentially leading to malabsorption and malnutrition.

About the AbbVie CF Scholarship
The AbbVie CF Scholarship was established over 30 years ago in recognition of the financial burdens many families touched by CF face and to acknowledge the achievements of students with CF. Since its inception, the scholarship program has awarded over $3.9 million in scholarships to over 1,000 students. The AbbVie CF Scholarship is part of AbbVie’s ongoing commitment to the CF community, which is comprised of close to 40,000 people in the United States. Today, more than half of the CF population are age 18 years or older.1

It is not necessary for scholarship applicants to have taken, currently take, or intend to take in the future, any medicine or product marketed by AbbVie, and this is not a consideration in the selection criteria. More information about the AbbVie CF Scholarship criteria and application can be found at www.AbbVieCFScholarship.com.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

References:

  1. Cystic Fibrosis Foundation. About Cystic Fibrosis. https://www.cff.org/intro-cf/about-cystic-fibrosis. Accessed August 2023.

US-PANC-230059

SOURCE AbbVie

Contact(s)

U.S. Media
Raquel Powers
+1 (847) 935-6563
raquel.powers@abbvie.com

Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn’s Disease

“Head-to-head studies like the SEQUENCE study are important in helping physicians understand differences in therapies and define treatment algorithms in clinical practice,” said Laurent Peyrin-Biroulet, M.D., Ph.D., director of the Infinity Institute, professor of gastroenterology and head of the Inflammatory Bowel Disease group at the Gastroenterology Department, University Hospital of Nancy, France. “These results add to our growing body of evidence for SKYRIZI in Crohn’s Disease. This study highlights the efficacy of SKYRIZI compared to ustekinumab in helping eligible patients achieve clinical and endoscopic treatment goals and also reinforces the safety profile observed in previous studies.”

Full results from the SEQUENCE study will be presented at a future medical meeting and submitted for publication in a peer-reviewed journal.

Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. 

About Crohn’s Disease
Crohn’s disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain.2,3 It is a progressive disease, meaning it gets worse over time in a substantial proportion of patients or may develop complications that require urgent medical care, including surgery.2,3 Because the signs and symptoms of Crohn’s disease are unpredictable, it causes a significant burden on people living with the disease—not only physically, but also emotionally and economically.2

About the SEQUENCE Study1
The SEQUENCE study is a Phase 3, multicenter, randomized, head-to-head study (study drug open-label and efficacy assessment blinded) to evaluate risankizumab with ustekinumab for the treatment of adults with moderate to severe Crohn’s disease with a history of one or more failed anti-tumor necrosis factor (TNF) therapies. All participants had confirmed diagnosis of Crohn’s disease for at least 3 months, Crohn’s Disease Activity Index (CDAI) score of 220 to 450 at baseline, confirmed diagnosis of moderate to severe Crohn’s disease assessed by stool frequency, abdominal pain score, Simple Endoscopy Score for Crohn’s Disease (SES-CD), and demonstrated intolerance or inadequate response to one or more anti-TNF therapies.

More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT04524611).

About Risankizumab (SKYRIZI®)

SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit.4 IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.5 SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of plaque psoriasis, psoriatic arthritis and Crohn’s disease. Phase 3 trials of risankizumab in psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis are ongoing.5-7

U.S. Indications and Important Safety Information about SKYRIZI® (risankizumab-rzaa)8
SKYRIZI is a prescription medicine used to treat adults with:

  • moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
  • active psoriatic arthritis (PsA).
  • moderate to severe Crohn’s disease.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

  • Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

–   fainting, dizziness, feeling lightheaded (low blood pressure)
–   swelling of your face, eyelids, lips, mouth, tongue, or throat
–   trouble breathing or throat tightness
–   chest tightness
–   skin rash, hives
–   itching

Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

  • Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

–  fever, sweats, or chills
–  cough
–  shortness of breath
–  blood in your mucus (phlegm)
–  muscle aches
–  warm, red, or painful skin or sores on your body different from your psoriasis
–  weight loss
–  diarrhea or stomach pain
–  burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions,
including if you:

  • have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
  • have an infection that does not go away or that keeps coming back.
  • have TB or have been in close contact with someone with TB.
  • have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
  • are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
  • become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

Liver problems in Crohn’s disease: A person with Crohn’s disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about
side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.